{"filing":{"accession_number":"0001672688-26-000134","cik":"0001672688","ticker":"ABSI","company_name":"Absci Corp","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"absc-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/absc-20260811.htm"},"events":[{"id":26942,"run_id":24506,"accession_number":"0001672688-26-000134","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Absci Corporation announced Q2 2026 financial results (revenue $0.3M, R\u0026D expenses $22.6M, SG\u0026A expenses $9.2M, net loss $33.2M, cash $201.1M) via press release on August 11, 2026, along with clinical trial updates including positive Phase 1 interim data from the HEADLINE trial of ABS-201 and a $100 million capital raise including a $40 million strategic investment from Eli Lilly.","company_name":"Absci Corp","ticker":"ABSI","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28246,"accession_number":"0001672688-26-000134","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Absci Corporation announced its financial results for Q2 2026 ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly revenue ($0.3M), R\u0026D expenses ($22.6M), SG\u0026A expenses ($9.2M), and net loss ($33.2M), along with balance sheet metrics showing cash of $201.1M. This is a standard quarterly earnings release disclosing results of operations and financial condition under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:16:58.884776+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28247,"accession_number":"0001672688-26-000134","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 8.01 disclosure references a presentation released on August 11, 2026, but the supplemental exhibits (EX-99.1 and EX-99.2) reveal that the company simultaneously released a comprehensive earnings announcement titled \"Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results.\" The earnings release includes Q2 2026 financial results (revenue, R\u0026D expenses, SG\u0026A expenses, net loss, cash position), clinical trial updates (positive Phase 1 interim data from HEADLINE trial of ABS-201), and a $100 million capital raise including a $40 million strategic investment from Eli Lilly. While Item 8.01 formally describes only the presentation, the substance of the disclosure is a material earnings release with financial results and significant operational updates.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:16:58.884776+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28246,"accession_number":"0001672688-26-000134","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Absci Corporation announced its financial results for Q2 2026 ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly revenue ($0.3M), R\u0026D expenses ($22.6M), SG\u0026A expenses ($9.2M), and net loss ($33.2M), along with balance sheet metrics showing cash of $201.1M. This is a standard quarterly earnings release disclosing results of operations and financial condition under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:16:58.884776+00:00","company_name":"Absci Corp","ticker":"ABSI","filing_date":"2026-08-11"},{"id":28247,"accession_number":"0001672688-26-000134","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 8.01 disclosure references a presentation released on August 11, 2026, but the supplemental exhibits (EX-99.1 and EX-99.2) reveal that the company simultaneously released a comprehensive earnings announcement titled \"Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results.\" The earnings release includes Q2 2026 financial results (revenue, R\u0026D expenses, SG\u0026A expenses, net loss, cash position), clinical trial updates (positive Phase 1 interim data from HEADLINE trial of ABS-201), and a $100 million capital raise including a $40 million strategic investment from Eli Lilly. While Item 8.01 formally describes only the presentation, the substance of the disclosure is a material earnings release with financial results and significant operational updates.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:16:58.884776+00:00","company_name":"Absci Corp","ticker":"ABSI","filing_date":"2026-08-11"}]}